MOESM1 of Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

Fuchigami, Ayako; Shigiyama, Fumika; Kitazawa, Toru; Okada, Yosuke; Ichijo, Takamasa; Higa, Mariko; Hiyoshi, Toru; Inoue, Ikuo; Iso, Kaoru; Yoshii, Hidenori; Hirose, Takahisa; Kumashiro, Naoki

doi:10.6084/m9.figshare.11543358.v1

12933_2019_977_MOESM1_ESM.doc (43.5 kB)

MOESM1 of Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

journal contribution

posted on 2020-01-08, 04:55 authored by Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii, Takahisa Hirose, Naoki Kumashiro

Additional file 1. Principal Investigators List.

Funding

AstraZeneca Japan K.K.

History

Usage metrics

Keywords

Type 2 diabetes Cardiometabolic risk factors Dapagliflozin Sitagliptin Glycemic control Weight loss Hypoglycemia

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM1 of Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

Funding

AstraZeneca Japan K.K.

History

Usage metrics

Categories

Keywords

Licence

Exports